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Background. Preeclampsia is diﬃcult to diagnose in patients with underlying renal disease and proteinuria. Prior studies show that
there is an angiogenic factor imbalance with elevated levels of antiangiogenic proteins soluble fms-like tyrosine kinase 1 (sFlt1)
and soluble endoglin (sEng) and reduced levels of the proangiogenic protein, placental growth factor (PlGF) in women with
preeclampsia. These angiogenic biomarkers may be useful in distinguishing preeclampsia from other conditions of pregnancy,
which may present with overlapping clinical characteristics. Cases. Case 1: A multiparous woman at 18 weeks gestation with
nephrotic syndrome presented with hypertensive emergency and worsening renal insuﬃciency. She underwent induction of labor
for severe preeclampsia. Her sFlt1 and sEng levels were at the 97 percentile while her PlGF level was undetectable (less than the 1st
percentile). Case 2: A nulliparous woman with lupus nephritis at 22 weeks gestation presented with fetal demise and heart failure.
Three weeks previously, the patient had developed thrombocytopenia and hypertensive urgency. She underwent dilation and
evacuation. Her angiogenic proﬁle was consistent with severe preeclampsia. Conclusion. Angiogenic factors may provide evidence
to support a diagnosis of preeclampsia in patients with preexisting renal disease and proteinuria, conditions in which the classical
deﬁnition of hypertension and proteinuria cannot be used.
1.Introduction
Preeclampsia aﬀects 5–7% of all pregnancies and is a leading
causeofmaternalandneonatalmorbidityandmortality.The
classical diagnosis of preeclampsia is made when pregnant
women present with new-onset hypertension (140mmHg
systolic or higher or 90mmHg diastolic or higher) and
proteinuria (0.3grams protein or higher in a 24-hour urine
specimen) typically after 20 weeks of gestation [1]. However,
preeclampsia can be challenging to diagnose using these
clinical criteria when a patient has preexisting renal disease
which itself causes hypertension or proteinuria.
The exact pathophysiology of preeclampsia remains un-
clear and is a leading area of investigation. Recent studies
have demonstrated angiogenic imbalance in patients with
preeclampsia. Weeks before the onset of preeclampsia, cir-
culating levels of the antiangiogenic factors soluble fms-like
tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng) rise
to abnormally high levels while levels of the proangiogenic
placental growth factor (PlGF) are reduced [2].
In this paper, we present two patients with underlying
renal disease and proteinuria who were diagnosed with
severe preeclampsia. Because of their preexisting medical
conditions and the fact that clinical onset of disease occurred
in the late second trimester, the diagnosis of preeclampsia
was challenging. IRB/Ethics Committee decided approval
was not required for this study.
Case 1. A 34-year-old gravida 2 para 1 at 17 weeks 6 days of
gestation presented to the emergency room from an oﬃce
evaluation with hypertensive urgency. Her blood pressure
on arrival was 164/110mmHg. The patient had known
nephrotic syndrome with a baseline creatinine of 1.4mg/dL
and a 24-hour urine with 3.7grams of protein prior to
pregnancy. She had no preexisting hypertension. A week
prior to presentation, her creatinine had risen to 2.5mg/dL
and her 24-hour urine revealed 9.1grams of protein. The
patient’s elevated blood pressures were treated with labetalol.
Her worsening hypertension and renal function at the time























Case 1 17.6 8.7 7.5–11.1 16.5 6.9–9.3 5 77–53
Case 2 21.6 21.7 7.7–9.1 120.1 6.6–10.1 3 136–103
∗The percentiles for normal pregnancies were obtained from the CPEP study [3]. The values at 18 weeks are given for comparison with patient values at 17.6
weeks; values at 21-22 weeks are given for comparison with patient values at 21.6 weeks. PlGF: placental growth factor; sEng: soluble endoglin; sFlt1: soluble
fms-like tyrosine kinase-1.
pregnancy. On presentation to the emergency room, she
complained of a mild headache but denied any visual change
or epigastric pain. Her physical exam was signiﬁcant for 3+
deep tendon reﬂexes and 3+ pitting edema bilaterally.
The patient’s obstetric history included a preterm cesare-
an delivery at 24 weeks for severe preeclampsia with HELLP
syndrome. Given her current presentation and her obstetric
history, the patient was admitted and placed on intravenous
magnesium sulfate for seizure prophylaxis. She had a strong
desiretocontinueherpregnancy.Duringthehospitalcourse,
herbloodpressuresrequiredmultipleintravenousantihyper-
tensive medications. She developed elevated transaminases,
thrombocytopenia, and worsening renal function. Serum
creatinine was elevated at 2.6mg/dL, and uric acid was
7.0mg/dL.
The patient was counseled regarding the poor prognosis
ofthe pregnancy atthis previablegestational ageand the ma-
ternal risks associated with expectant management of severe
preeclampsia. The patient chose to undergo an induction of
labor at 18 weeks gestation.
Postpartum, her blood pressures, and elevated transam-
inases normalized, and her creatinine returned to baseline.
Placental pathology showed a preterm placenta with accel-
erated villous maturation, increased perivillous and intrav-
illous ﬁbrin deposition, multifocal extravillous cytotropho-
blast proliferation, and erythroblastosis.
Case 2. A 35-year-old gravida 1 para 0 with lupus nephritis
presented to the obstetrical triage unit at 21 6/7 weeks of
gestation with shortness of breath. Her medical history was
signiﬁcantforsystemiclupuserythematosus(SLE)withrenal
and hematological manifestations.
The patient had been recently admitted to the antepar-
tum service at 19 weeks 4 days of gestation for worsening
hypertension and thrombocytopenia. During her admission,
her blood pressure reached a maximum of 170/110mmHg
and her platelets reached a nadir of 50K/uL from 150K/uL
baseline prior to pregnancy. A 24-hour urine was signiﬁcant
for 3.4 grams of protein, increased from a baseline of 1.6
grams prior to pregnancy. She was started on two oral
antihypertensive medications and was administered oral and
intravenous steroids for what was thought to be an acute
lupus ﬂare. The worsening proteinuria, thrombocytopenia,
andhypertensionwerethoughttobesecondarytoworsening
SLE.
Following her ﬁrst antepartum discharge, the patient
presented to triage with new-onset shortness of breath and
decreased breath sounds bilaterally on physical examination.
A chest X-ray showed cardiomegaly and evidence of con-
gestive heart failure. Transabdominal ultrasound revealed
an intrauterine fetal demise. The patient underwent an
uncomplicated dilation and evacuation. Further workup of
acute heart failure revealed an ejection fraction of 30–35% as
well as pulmonary edema. She was admitted to the intensive
care unit for close supportive management. The patient’s
blood pressure improved requiring fewer medications for
control. Placental pathology showed extensive involvement
of perivillous ﬁbrin, hematomas, and infarcts. The fetus and
placenta were growth restricted.
Both patient’s clinical presentations presented diagnostic
challenges for experienced clinicians. We hypothesized that
these patients will have an angiogenic proﬁle unlike a normal
pregnancy, but similar to patients with severe preeclampsia.
Wecollectedserumsamplesfrombothpatientsatthetimeof
clinical presentation; enzyme-linked immunosorbent assays
(ELISA) for sFlt1, sEng, and PlGF were performed with
commercially available kits (R&D systems Inc, Minneapolis,
MN).Allassayswereperformedinduplicateandvaluesaver-
aged. The correlation coeﬃcient between duplicate results
forallthreebiomarkerswas0.99.Theselevelswerecompared
to those of gestational age-matched women from a random
sampleof2200womeninthetrialofCalciumforPreeclamp-
sia Prevention cohort who were normotensive at the time of
the blood collection [3].
We found that the levels of sFlt1 and sEng were at or
above the 95th percentile based on gestational age. Addition-
ally, PlGF levels were below the detection limit (15.6pg/mL)
in both patients, which corresponded to less than the 1st per-
centile as matched for gestational age (Table 1). We collected
this information in the hope that angiogenic proﬁles may be
used to assist the clinicians to conﬁrm a challenging clinical
diagnosis of severe preeclampsia even at an early gestational
age and aid in timely intervention in these patients.
2. Comment
The classic diagnosis of preeclampsia is based on new-onset
proteinuria and hypertension in the pregnant patient after
20 weeks of gestation [1]. Preeclampsia prior to 20 weeks of
gestation is rare but can occur in severe cases. Patients with
underlying renal disease and proteinuria prior to pregnancyCase Reports in Obstetrics and Gynecology 3
make the diagnosis of preeclampsia especially challenging
for the clinician. It is important to correctly distinguish
between proteinuria and hypertension secondary to chronic
renal disease from proteinuria and hypertension as a result
of preeclampsia because appropriate treatment may be either
delivery in the setting of preeclampsia or supportive man-
agement in the setting of chronic renal disease. Women with
preexisting renal disease are at increased risk for developing
preeclampsia, but not all women with renal disease develop
this complication.
Both patients in our report had underlying renal disease.
The ﬁrst patient had nephrotic syndrome. Although the
patient’s new-onset hypertension and her past history of a
preterm delivery for preeclampsia supported preeclampsia as
the diagnosis, her underlying renal disease as well as the early
gestational age at presentation made the clinical diagnosis
challenging.
The second patient had a longstanding history of SLE
with lupus nephritis and thrombocytopenia as manifesta-
tions of her lupus. She had baseline proteinuria of 1.6 grams
over 24 hours prior to pregnancy. Pregnancies complicated
by lupus nephritis are at increased risk of developing pree-
clampsia; similarly, there is a signiﬁcant risk of lupus ﬂare
during pregnancy [4]. This patient’s presentation made it
diﬃcult to distinguish a lupus ﬂare from preeclampsia at
20 weeks gestation; both diﬀerential diagnoses were likely.
Although this patient’s risk of developing preeclampsia was
high, her clinical presentation was initially attributed to a
lupusﬂare.Inbothpatients,theangiogenicproﬁlesupported
the diagnosis of preeclampsia with markedly elevated levels
of sFlt1 and sEng and undetectable PlGF levels.
Angiogenic biomarkers have demonstrated utility in dis-
tinguishingpreeclampsiafromlargecohortsofnormotensive
patients [2]. In prospective cohort studies, the ratio of
circulating anti- and proangiogenic protein levels identiﬁes
women with early onset preeclampsia with very high sensi-
tivity and speciﬁcity [5, 6]. Additionally, further reports have
usedangiogenicbiomarkerstohelpdiagnoseconditionswith
sign and symptoms similar to preeclampsia that limit the
usefulness of the classical deﬁnition such as thrombocytope-
nia [7], lupus [4], and renal diseases [8].
Qazi et al. demonstrated a diﬀerence in angiogenic fac-
tors among 52 patients with lupus who developed pree-
clampsia versus those that did not develop preeclampsia;
the authors concluded that angiogenic biomarkers could be
used prospectively to distinguish women with lupus at high
risk for developing preeclampsia. Women with lupus who
developed preeclampsia had signiﬁcantly higher levels of
sFlt1 versus patients with lupus but without preeclampsia
[4]. The sFlt1 levels in our patient with lupus were higher
than the cohort of patients in Qazi’s study.
Additionally, Williams et al. reported a case of a 29-
year-old woman with lupus and renal failure at 20 weeks 6
days gestation who presented with renal failure. The patient’s
diagnosis of preeclampsia was diﬃcult to conﬁrm clinically,
given her preexisting renal disease. The patient’s sFlt1 levels
were high, and PlGF levels in the serum were low, character-
istic of the angiogenic proﬁle of preeclampsia [9]. Similarly,
Shan et al. reported a case of a 34-year-old pregnant woman
at 29 weeks gestation with chronic hypertension and end-
stage renal disease on dialysis. She underwent an emergent
cesarean section for worsening hypertension. Soluble Flt1
and soluble endoglin levels were normal for gestational
age, however, suggesting that the hypertension noted during
pregnancy may not have resulted from preeclampsia [8].
Recently, Young et al. demonstrated that angiogenic bio-
markers may be used to distinguish gestational thrombocy-
topeniafromthrombocytopeniacausedbyHELLPsyndrome
[7].
The clinical diagnosis of preeclampsia is challenging to
conﬁrm or exclude in patients with underlying renal disease
and proteinuria who also develop hypertension. However,
accurate diagnosis is critical for appropriate obstetrical man-
agement particularly at early gestational ages.
Our two cases demonstrate that the measurement of
angiogenic biomarkers may help clinicians diagnose pree-
clampsia in patients with underlying renal disease with pro-
teinuria and hypertension that overlap with the classic diag-
nosis of preeclampsia. This is especially useful at previable
gestational ages where accurate and timely diagnosis is crit-
ical, as there is no fetal beneﬁt from prolongation of preg-
nancy. Prospective studies are needed to better characterize
theutilityoftheseangiogenicbiomarkersinreal-timeclinical
situations in which the patient’s comorbidities make the
classic diagnosis of preeclampsia diﬃcult to conﬁrm.
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